MedDataX Logo

Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye

NCT ID: NCT01404364

Last Updated: 2011-07-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy of intravitreal triamcinolone and retrobulbar chlorpromazine as alternatives in the management of ocular pain in blind eyes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The management of chronic eye pain is a constant challenge to ophthalmology. Treatment varies with the intensity of pain, and topical eye drops and contact lens therapy are effective in many patients. In refractory cases, and without vision, surgical removal of the eye through enucleation is considered classical therapy. As less invasive alternatives we have cyclodestruction and neurolytic drug injection in order to promote analgesia for a prolonged period.

The purpose of this study is to evaluate the efficacy of intravitreal triamcinolone and retrobulbar chlorpromazine as alternatives in the management of This is a prospective study of patients with blind painful eyes not responsive to topical treatment and with no indication for evisceration seen at the Department of Ophthalmology, Hospital Governador Celso Ramos (HGCR) in 2010.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blind Painful Eye Refractory Glaucoma Control of Pain Through Drug Injection

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Triamcinolone Chlorpromazine Refractory glaucoma Blind painful eye

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intravitreal Triamcinolone

Patients with phthisis bulbi received 0,3ml intravitreal triamcinolone injection

Group Type ACTIVE_COMPARATOR

Triamcinolone

Intervention Type DRUG

0,3mL intravitreal injection of Triamcinolone, single dose

Retrobulbar Chlorpromazine

Patients with refractory glaucoma and blind painful eye were submitted to 2,5mL Chlorpromazine retrobulbar injection

Group Type ACTIVE_COMPARATOR

Chlorpromazine

Intervention Type DRUG

2,5mL Chlorpromazine retrobulbar injection, single dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Triamcinolone

0,3mL intravitreal injection of Triamcinolone, single dose

Intervention Type DRUG

Chlorpromazine

2,5mL Chlorpromazine retrobulbar injection, single dose

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Amplictil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients treated in the period at HGCR who wanted to be part of the protocol by signing the consent form

Exclusion Criteria

* patients whose follow-up period was less than three months
Minimum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Governador Celso Ramos

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hospital Governador Celso Ramos

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Deborah C Ribas, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Governador Celso Ramos

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Governador Celso Ramos

Florianópolis, Santa Catarina, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HGCR-20101

Identifier Type: -

Identifier Source: org_study_id